Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
RYTM
vs
S&P 500
RYTM
S&P 500
Over the past 12 months, RYTM has underperformed S&P 500, delivering a return of -9% compared to S&P 500's +17% growth.
Stocks Performance
RYTM vs S&P 500
Performance Gap
RYTM vs S&P 500
Performance By Year
RYTM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Rhythm Pharmaceuticals Inc
Glance View
Rhythm Pharmaceuticals is a biopharmaceutical company that focuses on rare genetic diseases that cause severe obesity. Its main product is Imcivree, a prescription medicine used for certain patients whose body’s appetite-control pathway does not work properly. The company also develops follow-on treatments aimed at the same biology, especially the melanocortin-4 receptor pathway that helps regulate hunger and body weight. Rhythm sells to specialist doctors, hospitals, and specialty pharmacies that treat patients with these rare conditions. Its money comes mainly from selling its approved medicine, with additional value tied to developing and potentially expanding the use of its drug in other genetic obesity disorders. Because these diseases are uncommon and often diagnosed by specialists, the company relies on a focused commercial model rather than a broad primary-care sales force. What makes Rhythm different is that it is built around a narrow set of inherited disorders where the root problem is biologic, not lifestyle-driven. That gives the company a highly specialized role in the rare disease market: it works with physicians to identify the right patients, support diagnosis, and provide treatment for conditions that have few targeted options. For investors, the key point is that Rhythm’s business depends on proving and commercializing medicines for very specific genetic patient groups.
